CBLL2抗体;CBLL2 Antibody—艾普蒂 新品

The CBLL2 antibody targets the Cbl proto-oncogene-like 2 (CBLL2), also known as Hakai, an E3 ubiquitin ligase involved in post-translational protein modification. Initially identified in 2002. CBLL2 gained attention for its role in regulating epithelial-mesenchymal transition (EMT) by ubiquitinating and degrading E-cadherin, a key adhesion protein critical for maintaining epithelial cell integrity. This activity links CBLL2 to cancer metastasis, particularly in carcinomas where EMT promotes invasiveness. Structurally, CBLL2 contains a RING finger domain essential for its E3 ligase function, enabling substrate recognition and ubiquitination in coordination with E2 enzymes. Beyond cancer, CBLL2 participates in developmental processes, including neural and vascular development, as shown in zebrafish and mouse models. Its expression is tissue-specific, with elevated levels observed in certain cancers, suggesting potential as a biomarker or therapeutic target. Antibodies against CBLL2 are widely used in research to study its expression patterns, interaction networks (e.g., via immunoprecipitation), and functional roles in pathways like Wnt/β-catenin signaling. Commercial CBLL2 antibodies are typically validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. Ongoing studies explore its involvement in neurodegenerative diseases and immune regulation, underscoring its multifaceted biological significance.